Dr. Benjamin Ungar
Claim this profileIcahn School of Medicine at Mount Sinai
Studies Papulopustular Rosacea
Studies Acne Rosacea
4 reported clinical trials
4 drugs studied
Affiliated Hospitals
Clinical Trials Benjamin Ungar is currently running
PDE4 Inhibitor
for Skin Conditions
This study is a double-blind, vehicle-controlled clinical trial. The study will take place at Icahn School of Medicine at Mount Sinai. The study will include 33-39 adult subjects with moderate-to-severe-Seborrheic dermatitis (SD) as well as 33-39 adult subjects with moderate-to-severe papulopustular rosacea (PPR). Subjects will be randomized 2:1 to receive study drug or placebo. Enrolled subjects will apply topical PF-07038124 0.02% ointment once daily for 8 weeks. They will return for visits at weeks 4, 8, and 12 following study treatment initiation for repeat clinical assessments, medication reviews, tape-strip, blood and urine sample collections, and monitoring for adverse events.
Recruiting0 awards Phase 210 criteria
Deucravacitinib
for Rosacea
This will be a double-blind, randomized placebo-controlled study in which participants will be randomized 2:1 to receive 6 mg deucravacitinib or placebo once daily for 8 weeks, followed by an open label extension during which all participants will receive 6 mg deucravacitinib once daily for an additional 8 weeks. The open-label extension has been incorporated in order to ensure all participants receive benefit from the study, as well as to benefit from the intra-patient comparison of placebo to drug, and to provide longer-term clinical data. The study will include 33 adult participants with moderate-to-severe Papulopustular Rosacea (PPR). participants will have baseline Investigator Global Assessment (IGA) score of at least 3 and at least 12 inflammatory lesions. Beginning at Baseline/Week 0 enrolled participants will receive 6mg deucravacitinib or placebo once daily for 8 weeks. At week 8, those participants originally randomized to placebo will initiate dosing with 6mg deucravacitinib once daily for 8 weeks until Week 16. Participants previously randomized to deucravacitinib will continue to receive deucravacitinib for an additional 8 weeks until Week 16. All participants will return for visits at Weeks 4, 8, 12 and 16 following study treatment initiation for repeat clinical assessments, medication reviews, tape-strip collection, blood and urine sample collections, and monitoring for adverse events.
Recruiting0 awards Phase 23 criteria
More about Benjamin Ungar
Clinical Trial Related2 years of experience running clinical trials · Led 4 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Benjamin Ungar has experience with
- Deucravacitinib
- Duobrii
- PF-07038124
- Ruxolitinib
Breakdown of trials Benjamin Ungar has run
Papulopustular Rosacea
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Benjamin Ungar specialize in?
Benjamin Ungar focuses on Papulopustular Rosacea and Acne Rosacea. In particular, much of their work with Papulopustular Rosacea has involved treating patients, or patients who are undergoing treatment.
Is Benjamin Ungar currently recruiting for clinical trials?
Yes, Benjamin Ungar is currently recruiting for 2 clinical trials in New York New York. If you're interested in participating, you should apply.
Are there any treatments that Benjamin Ungar has studied deeply?
Yes, Benjamin Ungar has studied treatments such as Deucravacitinib, Duobrii, PF-07038124.
What is the best way to schedule an appointment with Benjamin Ungar?
Apply for one of the trials that Benjamin Ungar is conducting.
What is the office address of Benjamin Ungar?
The office of Benjamin Ungar is located at: Icahn School of Medicine at Mount Sinai, New York, New York 10029 United States. This is the address for their practice at the Icahn School of Medicine at Mount Sinai.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.